Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease

To the Editor: In the EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) trial, Cho et al. (Dec. 5 issue) 1 found that edoxaban monotherapy resulted in a lower risk of major or clinically relevant nonmajor bleeding than dual antithrombotic therapy, as well as in a similar risk of major ischemic events, at 12 months among patients with atrial fibrillation and stable coronary artery disease. The results of the EPIC-CAD trial differ from those of the AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) . . .